Edition:
United Kingdom

Synergy Pharmaceuticals Inc (SGYP.OQ)

SGYP.OQ on NASDAQ Stock Exchange Global Select Market

1.74USD
23 Apr 2018
Change (% chg)

$-0.01 (-0.57%)
Prev Close
$1.75
Open
$1.75
Day's High
$1.76
Day's Low
$1.72
Volume
398,803
Avg. Vol
1,268,778
52-wk High
$4.83
52-wk Low
$1.68

Chart for

About

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin... (more)

Overall

Beta: 1.20
Market Cap(Mil.): $431.66
Shares Outstanding(Mil.): 246.66
Dividend: --
Yield (%): --

Financials

  SGYP.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -1.00 -- --
ROI: -237.54 -0.74 13.19
ROE: -1,401.10 -2.80 15.00

BRIEF-Synergy Pharmaceuticals Qtrly Loss Per Share ‍$0.16

* SYNERGY PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND BUSINESS UPDATE

01 Mar 2018

BRIEF-Cipher Pharmaceuticals Acquires Exclusive Canadian Rights To FDA-Approved Trulance® From Synergy Pharma

* CIPHER PHARMACEUTICALS ACQUIRES EXCLUSIVE CANADIAN RIGHTS TO FDA-APPROVED TRULANCE® FROM SYNERGY PHARMACEUTICALS

28 Feb 2018

BRIEF-Paulson & Co Dissolves Share Stake In Sprint, Cuts In Synergy Pharmaceuticals ‍​

* PAULSON & CO CUTS SHARE STAKE IN SYNERGY PHARMACEUTICALS TO 4 MILLION SHARES FROM 24.1 MILLION SHARES - SEC FILING

14 Feb 2018

BRIEF-Synergy Pharma Meets Cash Balance Requirement

* SYNERGY PHARMACEUTICALS SAYS HAS MET CASH BALANCE REQUIREMENT TO ACCESS ADDITIONAL CAPITAL UNDER TERM LOAN AGREEMENT DATED SEPT 1, 2017 Source text for Eikon: Further company coverage:

01 Feb 2018

BRIEF-Synergy Pharmaceuticals Announces FDA Approval Of TRULANCE

* SYNERGY PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF TRULANCE® (PLECANATIDE) FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN ADULTS

25 Jan 2018

BRIEF-Synergy Pharmaceuticals Appoints Troy Hamilton Chief Executive Officer

* SYNERGY PHARMACEUTICALS APPOINTS TROY HAMILTON CHIEF EXECUTIVE OFFICER

19 Dec 2017

BRIEF-CVI Investments reports a 7.9 pct passive stake in Synergy Pharmaceuticals as of Nov 13, 2017

* CVI Investments Inc reports a 7.9 percent passive stake in Synergy Pharmaceuticals Inc as of November 13, 2017 - SEC Filing‍​ Source text: (http://bit.ly/2A4qbNI) Further company coverage:

22 Nov 2017

BRIEF-Synergy Pharma announces pricing of offering of common stock and warrants

* Synergy Pharmaceuticals announces pricing of offering of common stock and warrants

13 Nov 2017

BRIEF-Synergy Pharma files for a potential mixed shelf offering ‍​

* Synergy Pharmaceuticals Inc files for a potential mixed shelf offering; size undisclosed - SEC filing ‍​ Source text: (http://bit.ly/2mihpZ2) Further company coverage:

13 Nov 2017

BRIEF-Synergy Pharmaceuticals posts Q3 loss per share $0.22

* Synergy Pharmaceuticals reports third quarter 2017 financial results and business update

09 Nov 2017

Earnings vs. Estimates